#United States #San Rafael #BioMarin #n-Lorem #ReNU_Syndrome

BioMarin and n-Lorem Foundation Collaboration: A New Hope for ReNU Syndrome

In a significant scientific advancement, BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have formed a strategic alliance aimed at developing an innovative medicine for ReNU syndrome, a rare neurodevelopmental condition.

Understanding ReNU Syndrome

ReNU syndrome was identified as a distinct genetic disorder in 2024. It is caused by variations in the RNU4-2 gene and manifests severe cognitive, language, and behavioral challenges. With an estimated global prevalence of about 100,000 cases, many patients currently face the reality of living without approved treatments for this affliction.

The urgency of treating ReNU syndrome cannot be overstated. Thankfully, BioMarin's collaboration with n-Lorem aims to fill this treatment void by focusing on the development of an antisense oligonucleotide (ASO) candidate tailored to target the genetic mutations causing this disease. This pioneering approach leverages BioMarin's strengths in genetic therapy and n-Lorem's expertise in antisense technology.

The Strategic Collaboration

Under the terms of their partnership, both organizations will engage in preclinical investigations to identify a lead ASO candidate that will enter clinical trials. The focus will be on the variant RNU4-2 (n.64_65insT), which is believed to be responsible for approximately 75% of ReNU syndrome cases.

Dr. Kevin Eggan, Chief Scientific Officer at BioMarin, emphasized the groundbreaking nature of this initiative: "For many families, a ReNU diagnosis can finally provide answers, but currently, there are no approved medicines that address the underlying cause of the disease. By combining BioMarin's expertise in genetic medicines with n-Lorem's pioneering antisense capabilities, we aim to bring the first treatment option for people living with ReNU syndrome."

This partnership is especially vital considering the n-Lorem Foundation's mission focuses on assisting patients who fall into the 'nano-rare' category—that is, those whose conditions affect only a handful of individuals—generally fewer than 30 patients worldwide. When conditions warrant a wider-reaching therapeutic approach, n-Lorem actively seeks partnerships to help facilitate development, such as the ongoing collaboration with BioMarin.

The Path Forward

This collaboration marks an essential step toward addressing the unmet medical needs of ReNU syndrome patients globally. In the months to come, n-Lorem will initiate individualized clinical trials for patients diagnosed with this genetic anomaly while continuing to work closely with BioMarin to advance development.

Dr. Stanley T. Crooke, the founder and CEO of n-Lorem, articulated his enthusiasm for the partnership: "We are proud to partner with BioMarin, a company that shares our urgency and has the scientific, clinical, and commercial expertise to bring this innovative new medicine to better help people living with ReNU Syndrome globally."

Conclusion

The potential for a viable treatment for ReNU syndrome through this collaboration has ignited hope within the community affected by this condition. With over 475 treatment applications and 275 nano-rare patients approved under n-Lorem’s initiative, this partnership exemplifies the forward-thinking approaches in genetic medicine today. Through shared urgency and expertise, BioMarin and n-Lorem are on a promising path to potentially pioneering medical advancements that could transform the landscape of rare disease treatment.

For more information, visit BioMarin and n-Lorem.